Biopharma

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces FDA Has Lifted the Cli...

Feb 9, 2025 0

CAMBRIDGE, Mass.-- January 21, 2025 (BUSINESS WIRE)-- Amylyx Pharmaceuticals, I...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025 0

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasda...

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025 0

Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-...

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Receives Orphan Drug Designation from the U.S. ...

Feb 9, 2025 0

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2025-- Zai Lab Limited (N...

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma Announces Positive Results from ALLEVIATE-1...

Feb 9, 2025 0

MONMOUTH JUNCTION, NJ, January 22, 2025 – Tris Pharma, Inc. (Tris), a commercial...

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

March Biosciences Receives FDA Orphan Drug Designation ...

Feb 9, 2025 0

HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an eme...

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Novo Nordisk Successfully Completes Phase 1b/2a Trial w...

Feb 9, 2025 0

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline result...

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

Findings From Pivotal Nipocalimab Phase 3 Study in a Br...

Feb 9, 2025 0

SPRING HOUSE, Pa., (January 23, 2025) – Johnson & Johnson (NYSE: JNJ) today anno...

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Announces First Patients Entered into Pivotal P...

Feb 9, 2025 0

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE...

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint Announces Positive Six-Month Results for the P...

Feb 9, 2025 0

WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, In...

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Adicet Bio Receives FDA Fast Track Designation for ADI-...

Feb 9, 2025 0

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Feb. 5, 2025-- Adicet Bio, Inc. ...

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025 0

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, ...

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR ...

Feb 9, 2025 0

RICHMOND, Calif.--(BUSINESS WIRE)--Feb. 6, 2025-- Sangamo Therapeutics, Inc. (Na...

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer

Gradalis Secures FDA Regenerative Medicine Advanced The...

Feb 9, 2025 0

DALLAS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biote...

Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Arbor Biotechnologies Announces FDA Orphan Drug and Rar...

Feb 9, 2025 0

CAMBRIDGE, MA – February 5, 2025 – Arbor Biotechnologies™, a biotechnology compa...

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expand...

Feb 9, 2025 0

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasd...

Three drug cocktail shows potential to boost CAR-T canc...

Feb 9, 2025 0

Preclinical research findings from the University of North Carolina Lineberger C...

Bracco Imaging Receives FDA Fast Track Designation for BR55

Bracco Imaging Receives FDA Fast Track Designation for ...

Feb 9, 2025 0

MILAN - February 6, 2025 -- Bracco Imaging, a global leader in diagnostic imagin...

New tool for synthetic biology

Feb 9, 2025 0

Scientists at the University of Stuttgart have succeeded in controlling the stru...

AI-designed proteins neutralize snake toxins

Feb 9, 2025 0

A new study in Nature by last year's Nobel Laureate in Chemistry reveals a possi...

New computer models open door to far more targeted anti...

Feb 9, 2025 0

With antibiotic resistance a growing problem, University of Virginia School of M...

Short-course antibiotics can revolutionize healthcare

Feb 9, 2025 0

Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR)...

Drug in clinical trials for breast cancer could also tr...

Feb 9, 2025 0

Two new studies led by researchers at Washington University School of Medicine i...

One of the largest global surveys of society's att...

Feb 9, 2025 0

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Lea...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.